Review of the TAXUS Liberté SR paclitaxel-eluting coronary stent.
The advent of drug-eluting stents has revolutionized the treatment of coronary heart disease. Interventional cardiologists are increasingly treating more complex lesions in patients that would have otherwise required bypass surgery. As a result of technological advances, the second-generation thin strut TAXUS stent--the TAXUS Liberté SR paclitaxel-eluting coronary stent--has now been introduced into routine clinical practice. The Liberté stent has evolved from the currently available TAXUS Express stent to provide enhanced lesion access in challenging anatomies as well as more uniform drug delivery. This article will provide an overview of the TAXUS Liberté stent.
Ahmed
Waqar Habib
WH
Armed Forces Hospital, PO Box 8649, Jeddah 21492, Saudi Arabia. waqar@post.harvard.edu
D001807:Blood Vessel Prosthesis; D023903:Coronary Restenosis / Q000209:etiology / Q000517:prevention & control; D003331:Coronary Vessels / Q000187:drug effects* / Q000601:surgery*; D016503:Drug Delivery Systems / Q000295:instrumentation* / Q000379:methods; D004343:Drug Implants / Q000008:administration & dosage*; D006083:Graft Occlusion, Vascular / Q000209:etiology / Q000517:prevention & control; D006801:Humans; D017239:Paclitaxel / Q000008:administration & dosage*; D011474:Prosthesis Design; D015607:Stents
D004343:Drug Implants; D017239:Paclitaxel